Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Decrease in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 85,900 shares, a drop of 17.7% from the August 15th total of 104,400 shares. Based on an average daily trading volume, of 1,450,000 shares, the days-to-cover ratio is presently 0.1 days.

Biodexa Pharmaceuticals Price Performance

BDRX stock traded up $0.01 on Tuesday, reaching $0.41. 17,010 shares of the company’s stock were exchanged, compared to its average volume of 2,517,031. Biodexa Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $8.81. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average of $0.65 and a 200-day moving average of $0.92.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.